Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Golden Throat (6896 HK): Scheme Doc Out. Court Meeting On 30 November

Golden Throat (6896 HK): This One Left A Bitter Aftertaste

Asian Dividend Gems: Golden Throat Holdings

Quiddity Advisors

Event-Driven

<div>
<p>Following a <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0805/2021080500377.pdf" target="_blank" rel="noopener">suspension</a> "<em>pursuant to the Code of Takeovers and Mergers</em>" on the 5 August  <a href="https://www.smartkarma.com/entities/golden-throat-holdings-group" target="_blank" data-smartkarma-citation="entities:22664:1" rel="noopener">Golden Throat Holdings (6896 HK)</a>, a leading manufacturer of lozenges in China, has now <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0812/2021081200754.pdf" target="_blank" rel="noopener">announced</a> an Offer from PE outfit Affirma, by way of a Scheme, at HK$2.80/share, a 55.6% premium to the undisturbed price.</p>
<p>The Offer Price will not be increased. Golden Throat does not intend to declare any dividends during the Offer period. </p>
<p>Both the Founder Group and Rollover Shareholders have given Affirma irrevocables.</p>
<p>The Founder Group collectively holds 457,076,300 shares or 61.33% of shares out. These shares form part of the Scheme shares. The Rollover Shareholders collectively hold 92,956,400 shares or 12.57% of shares out.</p>
</div>
<p>Standard Scheme conditions apply. None of the Founder Shareholders nor the Rollover Shareholders will attend or vote at the Court Meeting to approve the Scheme, nor vote at the General Meeting on the ordinary resolution to approve the Rollover Arrangement.</p>
<div>
<p>This Offer looks done.</p>
</div>
<div>
<p>More below the fold.</p>
</div>


Following a suspension "pursuant to the Code of Takeovers and Mergers" on the 5 August  Golden Throat Holdings (6896 HK), a leading manufacturer of lozenges in China, has now announced an Offer from PE outfit Affirma, by way of a Scheme, at HK$2.80/share, a 55.6% premium to the undisturbed price.
The Offer Price will not be increased. Golden Throat does not intend to declare any dividends during the Offer period. 
Both the Founder Group and Rollover Shareholders have given Affirma irrevocables.
The Founder Group collectively holds 457,076,300 shares or 61.33% of shares out. These shares form part of the Scheme shares. The Rollover Shareholders collectively hold 92,956,400 shares or 12.57% of shares out.

Standard Scheme conditions apply. None of the Founder Shareholders nor the Rollover Shareholders will attend or vote at the Court Meeting to approve the Scheme, nor vote at the General Meeting on the ordinary resolution to approve the Rollover Arrangement.

This Offer looks done.


More below the fold.


Golden Throat (6896 HK): Affirma and Founder Group Cough Up